Pralsetinib: First Approval

Author:

Markham Anthony

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Reference12 articles.

1. Zhao Z, Fu T, Gao J, et al. Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors. J Med Genet. 2020;13:13.

2. Blueprint Medicines. Blueprint Medicines announces FDA approval of GAVRETO™ (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer [media release]. 4 Sept 2020 https://www.blueprintmedicines.com .

3. US Food and Drug Administration. GAVRETO™ (pralsetinib) capsules, for oral use: US prescribing information. 2020. https://www.blueprintmedicines.com/uspi/GAVRETO.pdf . Accessed 18 Sept 2020.

4. Blueprint Medicines, CStone Pharmaceuticals. Blueprint Medicines and CStone Pharmaceuticals announce exclusive collaboration and license agreement to develop and commercialize avapritinib, BLU-554 and BLU-667 in greater China [media release]. 4 June 2018 https://www.blueprintmedicines.com .

5. Blueprint Medicines. Blueprint Medicines announces global collaboration with Roche to develop and commercialize pralsetinib for patients with RET-altered cancers [media release]. 13 July 2020 https://www.blueprintmedicines.com .

Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3